Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus

[1]  Johannes D Veldhuis,et al.  Postprandial suppression of glucagon secretion depends on intact pulsatile insulin secretion: further evidence for the intraislet insulin hypothesis. , 2006, Diabetes.

[2]  J. Holst,et al.  Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. , 2006, Gastroenterology.

[3]  M. Nauck,et al.  Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes , 2006, Diabetologia.

[4]  J. Holst,et al.  On the Physiology of GIP and GLP-1 , 2004, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[5]  R. Robertson,et al.  Regulation of α-Cell Function by the β-Cell During Hypoglycemia in Wistar Rats: the “Switch-off” Hypothesis , 2004 .

[6]  S. Dinneen,et al.  Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM , 1995, Diabetologia.

[7]  J. Holst,et al.  Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients , 1993, Diabetologia.

[8]  W. Creutzfeldt,et al.  Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets , 1985, Diabetologia.

[9]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[10]  J. Holst,et al.  Glucagon-related peptides in the human gastrointestinal mucosa , 1984, Diabetologia.

[11]  J. Holst,et al.  Circulating glucagon after total pancreatectomy in man , 1983, Diabetologia.

[12]  R. Robertson,et al.  Regulation of alpha-cell function by the beta-cell during hypoglycemia in Wistar rats: the "switch-off" hypothesis. , 2004, Diabetes.

[13]  T. Hansen,et al.  The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. , 2003, The Journal of clinical endocrinology and metabolism.

[14]  J. Holst,et al.  Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. , 2003, The Journal of clinical endocrinology and metabolism.

[15]  J. Holst,et al.  Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia , 2003, Diabetologia.

[16]  A. Astrup,et al.  No effect of physiological concentrations of glucagon-like peptide-2 on appetite and energy intake in normal weight subjects† , 2003, International Journal of Obesity.

[17]  J. Holst,et al.  The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. , 2003, Diabetes.

[18]  P. Raskin,et al.  Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.

[19]  J. Holst,et al.  Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients , 2002, Diabetologia.

[20]  P. Cryer,et al.  Intraislet hyperinsulinemia prevents the glucagon response to hypoglycemia despite an intact autonomic response. , 2002, Diabetes.

[21]  J. Holst,et al.  Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. , 2001, The Journal of clinical endocrinology and metabolism.

[22]  J. Holst,et al.  Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. , 2001, Diabetes.

[23]  R. Rizza,et al.  Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. , 2000, The Journal of clinical endocrinology and metabolism.

[24]  J. Holst,et al.  Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. , 2000, The Journal of clinical endocrinology and metabolism.

[25]  E. Ipp.  Impaired glucose tolerance: the irrepressible alpha-cell? , 2000, Diabetes care.

[26]  R. Bergman,et al.  Validation of methods for measurement of insulin secretion in humans in vivo. , 2000, Diabetes.

[27]  P. Zimmet,et al.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[28]  J. Holst,et al.  Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans , 1994, Diabetes.

[29]  J. Holst,et al.  Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. , 1993, The Journal of clinical investigation.

[30]  J. Holst,et al.  Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. , 1991, The Journal of clinical investigation.

[31]  T. Jenssen,et al.  Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM. , 1990, Diabetes.

[32]  V. Marks,et al.  The order of islet microvascular cellular perfusion is B----A----D in the perfused rat pancreas. , 1988, The Journal of clinical investigation.

[33]  A. Baron,et al.  Role of Hyperglucagonemia in Maintenance of Increased Rates of Hepatic Glucose Output in Type II Diabetics , 1987, Diabetes.

[34]  A. Golay,et al.  Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. , 1987, The Journal of clinical endocrinology and metabolism.

[35]  J. Holst,et al.  Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. , 1986, Endocrinology.

[36]  J. Holst,et al.  The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera , 1984, Regulatory Peptides.

[37]  J. Holst,et al.  Diminished immunoreactive gastric inhibitory polypeptide response to a meal in newly diagnosed type I (insulin-dependent) diabetics. , 1983, The Journal of clinical endocrinology and metabolism.

[38]  G. Bell,et al.  Hamster preproglucagon contains the sequence of glucagon and two related peptides , 1983, Nature.

[39]  L. Orci,et al.  Glucagon and the A cell: physiology and pathophysiology (first two parts). , 1981, The New England journal of medicine.

[40]  L. Orci,et al.  Glucagon and the A cell: physiology and pathophysiology (second of two parts). , 1981, The New England journal of medicine.

[41]  P. Bennett,et al.  Immunoreactive glucagon (IRG) responses to intravenous glucose in prediabetes and diabetes among Pima Indians and normal Caucasians. , 1977, The Journal of clinical endocrinology and metabolism.

[42]  J. Gerich,et al.  Lack of Glucagon Response to Hypoglycemia in Diabetes: Evidence for an Intrinsic Pancreatic Alpha Cell Defect , 1973, Science.

[43]  W. A. Müller,et al.  Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. , 1970, The New England journal of medicine.